These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9009252)

  • 21. Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host disease.
    Glass B; Uharek L; Gassmann W; Focks B; Bolouri H; Loeffler H; Mueller-Ruchholtz W
    Ann Hematol; 1992 Jun; 64(6):255-9. PubMed ID: 1637877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia.
    Weiss L; Nusair S; Reich S; Sidi H; Slavin S
    Cancer Immunol Immunother; 1996 Oct; 43(2):103-8. PubMed ID: 8954144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation.
    Drobyski WR; Gendelman M; Vodanovic-Jankovic S; Gorski J
    J Immunol; 2003 Mar; 170(6):3046-53. PubMed ID: 12626559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Study on nonmyeloablative allogeneic bone marrow transplantation in the treatment of L615 leukemia mice].
    Xu KL; Ju JP; Pan XY; Du B; Li ZY; Lu QX
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):372-5. PubMed ID: 12941194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease.
    Aizawa S; Kamisaku H; Sado T
    Bone Marrow Transplant; 1995 Oct; 16(4):603-9. PubMed ID: 8528179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclosporine-induced syngeneic graft-vs-host disease: prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens.
    Hess AD; Horwitz LR; Laulis MK; Fuchs E
    Clin Immunol Immunopathol; 1993 Dec; 69(3):341-50. PubMed ID: 7694818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy.
    Weiss L; Reich S; Slavin S
    Cancer Invest; 1992; 10(1):19-26. PubMed ID: 1735011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia.
    Weiss L; Weigensberg M; Morecki S; Bar S; Cobbold S; Waldmann H; Slavin S
    Cancer Immunol Immunother; 1990; 31(4):236-42. PubMed ID: 2379219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of BCL1 leukemia by transplantation of low density fractions of allogeneic bone marrow and spleen cells.
    Palathumpat V; Holm B; Dejbakhsh-Jones S; Strober S
    J Immunol; 1992 May; 148(10):3319-26. PubMed ID: 1578152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders.
    Ackerstein A; Kedar E; Slavin S
    Blood; 1991 Sep; 78(5):1212-5. PubMed ID: 1878588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia.
    Leshem B; Vourka-Karussis U; Slavin S
    Cytokines Cell Mol Ther; 2000 Sep; 6(3):141-7. PubMed ID: 11140883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo radiosensitizing effects of recombinant interleukin 6 on radiation resistant BCL-1 B-lineage leukemia cells in a murine syngeneic bone marrow transplant model system.
    Waddick KG; Finnegan DM; Chelstrom LM; Uckun FM
    Leuk Lymphoma; 1995 Sep; 19(1-2):121-8. PubMed ID: 8574156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice.
    Vourka-Karussis U; Karussis D; Ackerstein A; Slavin S
    Exp Hematol; 1995 Mar; 23(3):196-201. PubMed ID: 7875238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of cyclosporine-induced syngeneic graft-versus-host disease in bone marrow transplantation by UV-B irradiated bone marrow cells.
    Ohajekwe OA; James T; Hardy MA; Oluwole SF
    Bone Marrow Transplant; 1995 Apr; 15(4):627-32. PubMed ID: 7655391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of cyclosporine A and methylprednisolone on the graft-versus-leukemia effects across major histocompatibility barriers in mice following allogeneic bone marrow transplantation.
    Weiss L; Reich S; Slavin S
    Bone Marrow Transplant; 1990 Oct; 6(4):229-33. PubMed ID: 2085696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B; Li DP; Xu KL; Pan XY
    Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Graft-versus-leukemia effect in allogeneic bone marrow transplantation in mice against several radiation-induced leukemias.
    Aizawa S; Sado T; Kamisaku H; Nemoto K; Yoshida K
    Bone Marrow Transplant; 1994 Feb; 13(2):109-14. PubMed ID: 8205078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graft-versus-leukemia effect.
    Glass B; Uharek L; Zeis M; Dreger P; Löffler H; Steinmann J; Schmitz N
    Blood; 1997 Aug; 90(4):1694-700. PubMed ID: 9269790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.